Back to results
US 8,633,219 B2Granted
Combination therapy
AssigneeJapan Tobacco Inc.
InventorsYuji Matsuzaki, Wataru Watanabe, Satoru Ikeda, Mitsuki Kano
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeJapan Tobacco Inc.
InventorsYuji Matsuzaki, Wataru Watanabe, Satoru Ikeda, Mitsuki Kano
Estimating the term…
The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.
A method for treating an HIV infectious disease in a human patient comprising administering to the patient a combination of:
A method for treating an HIV infectious disease in a human patient comprising administering to the patient a combination of:
A composition for treating an HIV infectious disease in a human patient comprising:
A composition for treating an HIV infectious disease in a human patient comprising:
Dependencies are inferred from the claim text.